N/A
N=29
Efficacy of Cantharidin in Molluscum Contagiosum
Molluscum Contagiosum, Skin Disease
Bottom Line
View on ClinicalTrials.gov: NCT00667225 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jun 2011
Primary outcome: Primary: Patients Experiencing Complete Clearance of All Molluscum Lesions. — 1; 3 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- cantharidin's vehicle (Drug); Cantharidin 0.7% (Drug)
- Age
- Pediatric · 5+ yrs
- Sex
- All
- Sponsor
- University of North Carolina, Chapel Hill
- Primary completion
- Jun 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patients Experiencing Complete Clearance of All Molluscum Lesions. |
1; 3 | — |
| SECONDARY Mean Change in Each Group Measured by Lesion Count. |
26.26; 35.61 | — |
Summary
The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on the skin. It goes away on its own, though can last several months to several years. Cantharidin is a topical medicine which is applied at the clinic visit. It is well tolerated by the majority of children.
Eligibility Criteria
Inclusion Criteria
- Anyone aged 5-10 years with the clinical diagnosis of molluscum contagiosum.
Exclusion Criteria
- Anyone with immunosuppression including HIV or previous organ transplantation.
- Anyone taking immunosuppressive medications.
- Anyone who has previously received treatment with cantharidin.
- Any female who has had her first menstrual period.
Data sourced from ClinicalTrials.gov (NCT00667225). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.